Top

Published in:

Open Access 01-10-2020 | Hypotension | Therapy in Practice

Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications

Authors: Giulia Rivasi, Martina Rafanelli, Enrico Mossello, Michele Brignole, Andrea Ungar

Published in: Drugs & Aging | Issue 10/2020

Abstract

Orthostatic hypotension (OH) is an abnormal blood pressure response to standing, which is associated with an increased risk of adverse outcomes such as syncope, falls, cognitive impairment, and mortality. Medical therapy is one the most common causes of OH, since numerous cardiovascular and psychoactive medications may interfere with the blood pressure response to standing, leading to drug-related OH. Additionally, hypotensive medications frequently overlap with other OH risk factors (e.g., advanced age, neurogenic autonomic dysfunction, and comorbidities), thus increasing the risk of symptoms and complications. Consequently, a medication review is recommended as a first-line approach in the diagnostic and therapeutic work-up of OH, with a view to minimizing the risk of drug-related orthostatic blood pressure impairment. If symptoms persist after the review of hypotensive medications, despite adherence to non-pharmacological interventions, specific drug treatment for OH can be considered. In this narrative review we present an overview of drugs acting on the cardiovascular and central nervous system that may potentially impair the orthostatic blood pressure response and we provide practical suggestions that may be helpful to guide medical therapy optimization in patients with OH. In addition, we summarize the available strategies for drug treatment of OH in patients with persistent symptoms despite non-pharmacological interventions.

Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161:46–8.PubMed

Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. Practical Instructions for the 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):e43–80.PubMed

Ceccofiglio A, Mussi C, Rafanelli M, et al. Increasing prevalence of orthostatic hypotension as a cause of syncope with advancing age and multimorbidity. J Am Med Dir Assoc. 2019;20:586–8.PubMed

Fedorowski A, Stavenow L, Hedblad B, et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J. 2010;31:85–91.PubMed

Wolters FJ, Mattace-Raso FU, Koudstaal PJ, Heart Brain Connection Collaborative Research Group, et al. Orthostatic hypotension and the long-term risk of dementia: a population-based study. PLoS Med. 2016;13:e002143.

Mossello E, Marchionni N. Vascular risk factors and cognitive function. the effect of aging process. In: Govoni S, et al., editors. Brain and heart dynamics. Switzerland: Springer Nature; 2020.

Smith JJ, Porth CM, Erickson M. Hemodynamic response to the upright posture. J Clin Pharmacol. 1994;34(5):375–86.PubMed

Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50(1):47–53.PubMed

Montastruc JL, Laborie I, Bagheri H, Senard JM. Drug-induced orthostatic hypotension. A five-year experience in a regional pharmacovigilance centre in France. Clin Drug Investig. 1997;14:61.

10.

ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 2007;14:488–98.PubMed

11.

Moonen JE, Foster-Dingley JC, de Ruijter W, van der Grond J, de Craen AJ, van der Mast RC. Effect of discontinuation of antihypertensive medication on orthostatic hypotension in older persons with mild cognitive impairment: the DANTE Study Leiden. Age Ageing. 2016;45(2):249–55.PubMed

12.

Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf. 1997;17(2):105–18.PubMed

13.

Chen A, Ashburn MA. Cardiac effects of opioid therapy. Pain Med. 2015;16(Suppl 1):S27–31.PubMed

14.

Fedorowski A, Burri P, Juul-Möller S, Melander O. A dedicated investigation unit improves management of syncopal attacks (Syncope Study of Unselected Population in Malmo–SYSTEMA I). Europace. 2010;12(9):1322–8.PubMedPubMedCentral

15.

Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in the British Women’s Heart and Health Study. Age Ageing. 2010;39(1):51–6.PubMed

16.

Mussi C, Ungar A, Salvioli G, Menozzi C, Bartoletti A, Giada F, Evaluation of Guidelines in Syncope Study 2 Group, et al. Orthostatic hypotension as cause of syncope in patients older than 65 years admitted to emergency departments for transient loss of consciousness. J Gerontol A Biol Sci Med Sci. 2009;64(7):801–6.PubMed

17.

Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30:173–8.PubMed

18.

Canney M, O’Connell MD, Murphy CM, O’Leary N, Little MA, O’Seaghdha CM, Kenny RA. Single agent antihypertensive therapy and orthostatic blood pressure behaviour in older adults using beat-to-beat measurements: the irish longitudinal study on ageing. PLoS One. 2016;11(1):e0146156.PubMedPubMedCentral

19.

Raiha I, Luutonen S, Piha J, Seppanen A, Toikka T, et al. Prevalence, predisposing factors, and prognostic importance of postural hypotension. Arch Intern Med. 1995;155:930–5.PubMed

20.

Wu JS, Yang YC, Lu FH, Wu CH, Wang RH, et al. Population-based study on the prevalence and risk factors of orthostatic hypotension in subjects with pre-diabetes and diabetes. Diabetes Care. 2009;32:69–74.PubMedPubMedCentral

21.

Rose KM, Tyroler HA, Nardo CJ, Arnett DK, Light KC, et al. Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities study. Am J Hypertens. 2000;13:571–8.PubMed

22.

Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation. 2006;114:630–6.PubMed

23.

Hiitola P, Enlund H, Kettunen R, Sulkava R, Hartikainen S. Postural changes in blood pressure and the prevalence of orthostatic hypotension among home-dwelling elderly aged 75 years or older. J Hum Hypertens. 2009;23(1):33–9.PubMed

24.

Cox JR, Admani AK, Agarwal ML, et al. Postural hypotension: body fluid compartments and electrolytes. Age Ageing. 1973;2(2):112–20.PubMed

25.

Shannon RP, Wei JY, Rosa RM, Epstein FH, Rowe JW. The effect of age and sodium depletion on cardiovascular response to orthostasis. Hypertension. 1986;8(5):438–43.PubMed

26.

Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639–43.

27.

Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing medications for chronic diseases management in primary care settings: a systematic review of randomized controlled trials. J Am Med Dir Assoc. 2018;19(11):923–35.PubMed

28.

Fedorowski A, Burri P, Melander O. Orthostatic hypotension in genetically related hypertensive and normotensive individuals. J Hypertens. 2009;27(5):976–82.PubMed

29.

Wong AK, Lord SR, Sturnieks DL, Delbaere K, Trollor JN, Close JC. Angiotensin system-blocking medications are associated with fewer falls over 12 months in community-dwelling older people. J Am Geriatr Soc. 2013;61(5):776–81.PubMed

30.

Press Y, Punchik B, Freud T. Orthostatic hypotension and drug therapy in patients at an outpatient comprehensive geriatric assessment unit. J Hypertens. 2016;34(2):351–8.PubMed

31.

Wojszel ZB, Kasiukiewicz A, Magnuszewski L. Health and functional determinants of orthostatic hypotension in geriatric ward patients: a retrospective cross sectional cohort study. J Nutr Health Aging. 2019;23(6):509–17.PubMedPubMedCentral

32.

Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15(3):193–9.PubMedPubMedCentral

33.

Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006;126:209–16.PubMed

34.

Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2017;11(11):CD012615.PubMed

35.

Montorsi F. Profile of silodosin. Eur Urol Suppl. 2010;9:491–5.

36.

Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E, European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–52.PubMed

37.

Fonseca J, da Silva MC. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin. Clin Drug Investig. 2015;35(1):7–18.PubMed

38.

Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ. 2013;347:f6320.PubMedPubMedCentral

39.

Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D’Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation. 1999;100(23):2336–43.PubMed

40.

Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E, European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–14.PubMed

41.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994–1003.PubMed

42.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.PubMed

43.

Ylitalo R, Kähönen M, Nieminen T, Kööbi T, Ylitalo P, Turjanmaa V. Effects of a mononitrate, a beta1-blocker and a dihydropyridine calcium channel blocker on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study in normotensive volunteers. Arzneimittelforschung. 2005;55(3):160–6.PubMed

44.

Milazzo V, Stefano CD, Servo S, Crudo V, Fulcheri C, Maule S, et al. Drugs and orthostatic hypotension: evidence from literature. J Hypertens. 2012;1:104. https://doi.org/10.4172/2167-1095.1000104.CrossRef

45.

Testa G, Ceccofiglio A, Mussi C, Bellelli G, Nicosia F, Bo M, Riccio D, Curcio F, Martone AM, Noro G, Landi F, Ungar A, Abete P. Hypotensive drugs and syncope due to orthostatic hypotension in older adults with dementia (syncope and dementia study). J Am Geriatr Soc. 2018;66(8):1532–7.PubMed

46.

Valbusa F, Labat C, Salvi P, Vivian ME, Hanon O, Benetos A, PARTAGE investigators. Orthostatic hypotension in very old individuals living in nursing homes: the PARTAGE study. J Hypertens. 2012;30(1):53–60.PubMed

47.

Juraschek SP, Appel LJ, Miller ER, Mukamal KJ, Lipsitz LA. Hypertension treatment effects on orthostatic hypotension and its relationship with cardiovascular disease. Hypertension. 2018;72(4):986–93.PubMedPubMedCentral

48.

Krum H, Conway EL, Broadbear JH, Howes LG, Louis WJ. Postural hypotension in elderly patients given carvedilol. BMJ. 1994;309(6957):775–6.PubMedPubMedCentral

49.

Oster JR, Epstein M. Use of centrally acting sympatholytic agents in the management of hypertension. Arch Intern Med. 1991;151(8):1638–44.PubMed

50.

Gaxatte C, Faraj E, Lathuillerie O, Salleron J, Deramecourt V, Pardessus V, Destailleur MH, Boulanger E, Puisieux F. Alcohol and psychotropic drugs: risk factors for orthostatic hypotension in elderly fallers. J Hum Hypertens. 2017;31(4):299–304.PubMed

51.

Amery AK, Bossaert H, Fagard RH, et al. Clonidine versus methyldopa: a double blind cross-over study comparing side effects of clonidine and methyldopa administered together with chlorthalidone at a dosage producing the same blood pressure lowering effect. Acta Cardiol. 1972;21(1):82–99.PubMed

52.

Forette F, McClaran J, Hervy MP, Bouchacourt P, Henry JF. Nicardipine in elderly patients with hypertension: a review of experience in France. Am Heart J. 1989;117(1):256–61.PubMed

53.

Kennelly SP, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, Crawford F, Lawlor BA, Kenny RA. Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry. 2011;26(10):1038–45.PubMed

54.

Romero-Ortuno R, O’Connell MD, Finucane C, Soraghan C, Fan CW, Kenny RA. Insights into the clinical management of the syndrome of supine hypertension–orthostatic hypotension (SH-OH): the Irish Longitudinal Study on Ageing (TILDA). BMC Geriatr. 2013;15(13):73.

55.

Di Stefano C, Milazzo V, Totaro S, Sobrero G, Ravera A, Milan A, Maule S, Veglio F. Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic. J Hum Hypertens. 2015;29(10):599–603.PubMed

56.

Opie LH. Profiles of calcium antagonists in cardiovascular disease with special reference to second-generation agents and amlodipine. Postgrad Med J. 1991;67(Suppl 5):S2–8.PubMed

57.

Egan BM, Fleissner MJ, Stepniakowski K, Neahring JM, Sagar KB, Ebert TJ. Improved baroreflex sensitivity in elderly hypertensives on lisinopril is not explained by blood pressure reduction alone. J. Hypertens. 1993;11:1113–20.PubMed

58.

Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst. 2000;1(1):40–5.PubMed

59.

Mahmud A, Feely J. Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens. 2002;15(12):1092–5.PubMed

60.

Capewell S, Capewell A. ‘First dose’ hypotension and venodilatation. Br J Clin Pharmacol. 1991;31(2):213–5.PubMedPubMedCentral

61.

Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999;13(4):275–81.PubMed

62.

Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang RY. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens. 2001;14(6 Pt 1):567–72.PubMed

63.

Haïat R, Piot O, Gallois H, Hanania G. Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril. French General Hospitals National College of Cardiologists. J Cardiovasc Pharmacol. 1999;33(6):953–9.PubMed

64.

Anthopoulos L, Apostolou T, Bonoris P, Foussas S, Lefkos N, Zombolos S. Comparative haemodynamic responses to the first dose of short- and long-acting ACE inhibitors in patients with congestive heart failure. Curr Med Res Opin. 2001;17(4):290–7.PubMed

65.

Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26(5):381–94.PubMed

66.

Marano G, Traversi G, Romagnoli E, et al. Cardiologic side effects of psychotropic drugs. J Geriatr Cardiol. 2011;8(4):243–53. https://doi.org/10.3724/SP.J.1263.2011.00243.CrossRefPubMedPubMedCentral

67.

Briggs R, Carey D, McNicholas T, Claffey P, Nolan H, Kennelly SP, Kenny RA. The association between antidepressant use and orthostatic hypotension in older people: a matched cohort study. J Am Soc Hypertens. 2018;12(8):597–604.e1.PubMed

68.

Briggs R, Carey D, Kennelly SP, Kenny RA. Longitudinal association between orthostatic hypotension at 30 seconds post-standing and late-life depression. Hypertension. 2018;71(5):946–54.PubMed

69.

Pacher P, Ungvari Z, Kecskemeti V, Koller A. Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca2+ sensitivity. Br J Pharmacol. 1999;127(3):740–6.PubMedPubMedCentral

70.

Ungvari Z, Pacher P, Kecskeméti V, Koller A. Fluoxetine dilates isolated small cerebral arteries of rats and attenuates constrictions to serotonin, norepinephrine, and a voltage-dependent Ca(2+) channel opener. Stroke. 1999;30(9):1949–54.PubMed

71.

Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6(6):469–80.PubMed

72.

Fuller RW, Holland DR, Yen TT, Bemis KG, Stamm NB. Antihypertensive effects of fluoxetine and L-5-hydroxytryptophan in rats. Life Sci. 1979;25:1237–42.PubMed

73.

Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195–235.PubMed

74.

Johnson EM, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry. 2006;14(9):796–802.PubMed

75.

Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol. 2008;28(1):32–8.PubMed

76.

Alexandrino-Silva C, Nadalini Mauá FH, de Andrade AG, de Toledo Ferraz Alves TC. Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms. J Psychopharmacol. 2008;22(2):214–6.

77.

Brunton LL, Parker KL, Blumenthal DK, Buxton ILO. Goodman and Gilman’s manual of pharmacology and therapeutics. 12th ed. New York: The Mac Graw Hill Company; 2011.

78.

Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4(4):331–55.PubMed

79.

Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–49.PubMedPubMedCentral

80.

Hartke RH Jr, Gonzalez-Rothi RJ, Abbey NC. Midazolam-associated alterations in cardiorespiratory function during colonoscopy. Gastrointest Endosc. 1989;35(3):232–8.PubMed

81.

Marty J, Gauzit R, Lefevre P, Couderc E, Farinotti R, Henzel C, Desmonts JM. Effects of diazepam and midazolam on baroreflex control of heart rate and on sympathetic activity in humans. Anesth Analg. 1986;65(2):113–9.PubMed

82.

Samuelson PN, Reves JG, Smith LR, Kouchoukos NT. Midazolam versus diazepam: different effects on systemic vascular resistance. A randomized study utilizing cardiopulmonary bypass constant flow. Arzneimittelforschung. 1981;31(12a):2268–9.PubMed

83.

Rivasi G, Kenny RA, Ungar A, Romero-Ortuno R. Effects of benzodiazepines on orthostatic blood pressure in older people. Eur J Intern Med. 2020;72:73–8.PubMed

84.

Shi SJ, Garcia KM, Meck JV. Temazepam, but not zolpidem, causes orthostatic hypotension in astronauts after spaceflight. J Cardiovasc Pharmacol. 2003;41(1):31–9.PubMed

85.

Zeegers A, van Wilgenburg H, Leeuwin RS. Cardiac effects of benzodiazepine receptor agonists and antagonists in the isolated rat heart: a comparative study. Life Sci. 1998;63(16):1439–56.PubMed

86.

Harding J, Kemper M, Weissman C. Midazolam attenuates the metabolic and cardiopulmonary responses to an acute increase in oxygen demand. Chest. 1994;106(1):194–200.PubMed

87.

Kamijo Y, Masuda T, Nishikawa T, Tsuruta H, Ohwada T. Cardiovascular response and stress reaction to flumazenil injection in patients under infusion with midazolam. Crit Care Med. 2000;28(2):318–23.PubMed

88.

Lechin F, van der Dijs B, Benaim M. Benzodiazepines: tolerability in elderly patients. Psychother Psychosom. 1996;65(4):171–82.PubMed

89.

Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol. 2008;23(Suppl 1):3–14.PubMed

90.

Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther. 2012;135(2):113–22.PubMed

91.

Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25(8):659–71.PubMed

92.

Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry. 1990;51:459–62.PubMed

93.

Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27(4):295–310.PubMed

94.

Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(2):228–34.PubMedPubMedCentral

95.

Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural hypotension in Parkinson’s disease: a longitudinal study on the effects of drug withdrawal. Mov Disord. 1999;14(2):246–51.PubMed

96.

Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004;143(3):371–8.PubMedPubMedCentral

97.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(5):501–5.PubMed

98.

Curcio F, Testa G, Ceccofiglio A, Martone AM, Riccio D, Nicosia F, Noro G, Bellelli G, Bo M, Mussi C, Landi F, Ungar A, Abete P. Memantine induces reflex syncope in elderly patients with dementia: results from the syncope and dementia study (SYD-Study). J Am Med Dir Assoc. 2020;21(1):130–2.PubMed

99.

Sharma NM, Cunningham CJ, Zheng H, et al. Hypoxia-inducible Factor-1a mediates increased sympathoexcitation via glutamatergic N-Methyld-Aspartate receptors in the paraventricular nucleus of rats with chronic heart failure. Circ Heart Fail. 2016;9:e003423.PubMedPubMedCentral

100.

Gallini A, Sommet A, Montastrue JL. French PharmacoVigilance network: does memantine induce bradycardia? Pharmacoepidemiol Drug Saf. 2008;17:877–81.PubMed

101.

Huang CF, Su MJ. Positive ionotropic action of NMDA receptor antagonist (+)-MK801 in rat heart. J Biomed Sci. 1999;6:387–98.PubMed

102.

Eschlböck S, Wenning G, Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm (Vienna). 2017;124(12):1567–605.PubMedPubMedCentral

103.

Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567–82.PubMedPubMedCentral

104.

Magkas N, Tsioufis C, Thomopoulos C, Dilaveris P, Georgiopoulos G, Sanidas E, et al. Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. J Clin Hypertens. 2019;21:546–54.

105.

Ali A, Ali NS, Waqas N, Bhan C, Iftikhar W, Sapna F, et al. Management of orthostatic hypotension: a literature review. Cureus. 2018;10(8):e3166.PubMedPubMedCentral

106.

Pittner H, Stormann H, Enzenhofer R. Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059. Arzneimittelforschung. 1976;26(12):2145–54.PubMed

107.

Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120–4.PubMed

108.

Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046–51.PubMed

109.

Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38–48.PubMed

110.

Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604–10.PubMed

111.

Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018;28(4):355–62. https://doi.org/10.1007/s10286-018-0529-8.CrossRefPubMedPubMedCentral

112.

Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol. 2015;66(7):848–60.PubMed

113.

Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology. 1999;53(9):2151–7.PubMed

114.

Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724–8.PubMed

115.

Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328–35.PubMedPubMedCentral

116.

Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord. 2015;30(5):646–54.PubMed

117.

Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101–7.PubMed

118.

Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis. 2014;4(1):57–65.PubMed

119.

Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11(4):235–42.PubMed

120.

Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet (Lond, Engl). 1987;2(8569):1170–2.

121.

Kachi T, Iwase S, Mano T, Sakoda S, Hayashi A, Yamamura Y, et al. Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology. 1988;38(7):1091–4.PubMed

122.

Kaufmann H, Oribe E, Yahr MD. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J Neural Transm Park Dis Dement Sect. 1991;3(2):143–8.PubMed

123.

Keating GM. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension. Drugs. 2015;75(2):197–206.PubMed

124.

Hale GM, Valdes J, Brenner M. The treatment of primary orthostatic hypotension. Ann Pharmacother. 2017;51(5):417–28.PubMed

125.

Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979;301(2):68–73.PubMed

126.

Campbell IW, Ewing DJ, Clarke BF. 9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy. Diabetes. 1975;24(4):381–4.PubMed

127.

Ong AC, Myint PK, Shepstone L, Potter JF. A systematic review of the pharmacological management of orthostatic hypotension. Int J Clin Pract. 2013;67(7):633–46.PubMed

128.

Hakamäki T, Rajala T, Lehtonen A. Ambulatory 24-hour blood pressure recordings in patients with Parkinson’s disease with or without fludrocortisone. Int J Clin Pharmacol Ther. 1998;36(7):367–9.PubMed

129.

Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med. 1992;232(2):139–45.PubMed

130.

van Lieshout JJ, ten Harkel ADJ, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res. 2000;10:35–42.PubMed

131.

Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74(9):1294–8.PubMedPubMedCentral

132.

Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513–8.PubMed

133.

Singer W, Opfer-Gehrking TL, Nickander KK, Hines SM, Low PA. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Clin Neurophysiol. 2006;23(5):476–81.PubMed

134.

Alam M, Smith G, Bleasdale-Barr K, Pavitt DV, Mathias CJ. Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. J Hypertens. 1995;13(12 Pt 2):1664–9.PubMed

135.

Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed). 1986;293(6543):353–4.PubMedCentral

136.

Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med. 1993;329(9):611–5.PubMed

137.

Rao SV, Stamler JS. Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin Auton Res. 2002;12(3):141–3.PubMed

Title: Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications
Authors: Giulia Rivasi
Martina Rafanelli
Enrico Mossello
Michele Brignole
Andrea Ungar
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Hypotension
Hypotension
Published in: Drugs & Aging / Issue 10/2020
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-020-00796-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2020

Correction to: Suitable Use of Injectable Agents to Overcome Hypoglycemia Risk, Barriers, and Clinical Inertia in Community-Dwelling Older Adults with Type 2 Diabetes Mellitus

Age-Related Lymphocyte Output During Disease-Modifying Therapies for Multiple Sclerosis

Predictors of Mortality in the Older Population: The Role of Polypharmacy and Other Medication and Chronic Disease-Related Factors

Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study

Optimizing the Treatment of Moderate-to-Severe Psoriasis in Older Adults

Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials